Sugi Predict

Sugi Predict / Compounds / SCHEMBL6692

SCHEMBL6692

SCHEMBL6692

CC(C)(C)OC(=O)NNCc1ccc(-c2ccccn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.44
▸ AKT1 P31749 1/20 0.43
▸ HCAR2 Q8TDS4 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ CYP17A1 P05093 1/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ EPHX1 P07099 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ KDM4D Q6B0I6 1/20 0.41
▸ ACACB O00763 1/20 0.41
▸ ACACA Q13085 1/20 0.41
▸ ABL1 P00519 1/20 0.40
▸ BCR P11274 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30637051 1.00 TRPV1 (0.44) TRPV1AKT1HCAR2GAACYP17A1
SCHEMBL30608878 0.89 AKT1 (0.52) TRPV1AKT1GAANAMPTEPHX1
SCHEMBL26847061 0.89 AKT1 (0.52) TRPV1AKT1GAANAMPTEPHX1
SCHEMBL7911949 0.87 HCAR2 (0.46) TRPV1HCAR2EPHX1CYP2D6EPHX2
SCHEMBL5749 0.84 CYP17A1 (0.44) GAACYP17A1NAMPTCYP2D6L3MBTL1
SCHEMBL6447258 0.83 HDAC1 (0.52) GAACYP17A1CA12CA1CA7
SCHEMBL13359960 0.82 HCAR2 (0.45) TRPV1HCAR2EPHX1CYP2D6EPHX2
SCHEMBL8229792 0.81 TNKS (0.47) HCAR2NAMPTEPHX1CYP2D6EPHX2
SCHEMBL4422174 0.81 AKT1 (0.53) TRPV1AKT1HCAR2NAMPTCA1
SCHEMBL30453099 0.81 AKT1 (0.53) TRPV1AKT1HCAR2NAMPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208906-A1 HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2024-06-27 — — US claimed
EP-4313933-A1 HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST Council of Scientific & Industrial Research (IN) 2024-02-07 — — EP claimed
CN-116987024-A Preparation method of atazanavir intermediate 浙江荣耀生物科技股份有限公司 2023-11-03 — — CN claimed
WO-2022208545-A1 HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-10-06 — — WO claimed
US-20140343290-A1 PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT RANBAXY LABORATORIES LIMITED (IN) 2014-11-20 — — US claimed
WO-2013014633-A1 PROCESS FOR PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT RANBAXY LABORATORIES LIMITED (IN) 2013-01-31 — — WO claimed
US-20120157687-A1 IMPROVED PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS PRIME EUROPEAN THERAPEUTICALS S.P.A. (IT) 2012-06-21 — — US claimed
CN-102459182-A Process for preparing arylpyridinyl compounds PRIME EUROP THERAPEUTICALS 2012-05-16 — — CN claimed
EP-2445882-A1 PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS Prime European Therapeuticals S.p.A. in forma abbreviata Euticals S.p.A. (IT) 2012-05-02 — — EP claimed
EP-2272831-A1 Process for the preparation of arylpyridinyl compounds Prime European Therapeuticals S.p.A. (IT) 2011-01-12 — — EP claimed
WO-2010149356-A1 PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS PRIME EUROPEAN THERAPEUTICALS S.P.A. (IT) 2010-12-29 — — WO claimed
EP-1274684-B1 PROCESS FOR THE PREPARATION OF ARYL-PYRIDINYL COMPOUNDS EUTICALS PRIME EUROP THERAPEUT (IT) 2005-05-25 — — EP claimed
US-6376678-B1 CATALYTIC REDUCTION OF THE CORRESPONDING HYDRAZONE COMPOUND SUMIKA FINE CHEMICALS CO., LTD. (JP) 2002-04-23 — — US claimed
US-12577205-B2 Hydrogenation of imines by palladium based catalyst COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-03-17 — — US disclosed
US-20240208906-A1 HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2024-06-27 — — US disclosed
EP-4313933-A1 HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST Council of Scientific & Industrial Research (IN) 2024-02-07 — — EP disclosed
CN-1216539-A Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 1999-05-12 — — CN disclosed
EP-0900210-A1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES Novartis AG (CH) 1999-03-10 — — EP disclosed
US-5849911-A Antivirally active heterocyclic azahexane derivatives NOVARTIS FINANCE CORPORATION (US) 1998-12-15 — — US disclosed
WO-1997040029-A1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES NOVARTIS AG (CH) 1997-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208906-A1 HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST IDH2, IDH3A, IDH3B TRPV1 4820/4885AKT1 1499/4885HCAR2 4138/4885
US-20140343290-A1 PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT DNPEP, NSUN2, JMJD7 TRPV1 4460/4885AKT1 4602/4885HCAR2 2590/4885
US-12577205-B2 Hydrogenation of imines by palladium based catalyst TAF1, PDK1, TAF5 TRPV1 2310/4885AKT1 2315/4885HCAR2 3401/4885
US-20120157687-A1 IMPROVED PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS BAZ2A, AOC2, ZRANB2 TRPV1 2254/4885AKT1 3410/4885HCAR2 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.